Fibromun (L19-TNF) is a fully-human immunostimulatory product, currently being tested in clinical trials in patients with cancer. It consists of the anti-EDB human antibody L19, fused to human TNF, a strong pro-inflammatory cytokine. Recombinant TNF (Beromun TM, Boehringer Ingelheim) has so far been approved only for certain clinical applications.
Fibromun has previously been studied in clinical trials in melanoma in the isolated limb-perfusion setting and in a systemic clinical trial.
Fibromun is currently being studied in combination with doxorubicin in a Phase I trial in patients with Soft Tissue Sarcoma.
An additional Phase III trial in Soft Tissue Sarcoma is also in preparation.
Hemmerle and Neri (2013) Br. J. Cancer 109 (5) 1206-13;
Papadia et al. (2013) J Surg Oncol., 107, 173-179;
Spitaleri et al (2013) J Cancer Res. Clin. Onc., 139, 447-455;
Balza et al. (2010) Int. J. Cancer, 127 (1) 101-10;
Balza et al. (2006) Clin. Cancer Res., 12, 2575-2582;
Borsi et al. (2003) Blood, 102, 4384-4392;
Halin et al (2003) Cancer Res., 63 (12) 3202-10.